Login

Ask AI

Companies $NYMXF

$0.00 +$0.00 (0.0%) Close

$NYMXF Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Nymox Pharmaceutical Corp

What Do They Do?

Develops its drug candidate for enlarged prostate and low-grade localized prostate cancer.

Financial Snapshot

Last updated: 10/27/2026

Size

Revenue: N/A
Net Income: N/A

Growth

Revenue Growth: N/A
EPS Growth: N/A

Profitability

Gross Margin: N/A
Operating Margin: N/A
Net Income Margin: N/A

Cash flow

Free Cash Flow: N/A

Balance sheet 2025 Q4

Cash
Debt to Equity

Valuation Today

Market Cap: $4.31M
P/E: N/A

Company Facts

Industry: In Vitro & in Vivo Diagnostic Substances
Incorporated

Loading...

Comments